CNS Pharmaceuticals (CNSP) Capital Expenditures (2019 - 2024)
CNS Pharmaceuticals' (CNSP) quarterly Capital Expenditures came in at $4188.0 in Q4 2024, up 94.16% YoY from $2157.0 in Q1 2024, and up 94.16% on a QoQ basis from $2157.0 in Q4 2023.
CNS Pharmaceuticals (CNSP) Capital Expenditures (2019 - 2024) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 6 years of Capital Expenditures data on file, last reported at $4188.0 in Q4 2024.
- Quarterly Capital Expenditures rose 94.16% year-over-year to $4188.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $8088.0 (up 49.39% YoY) and the FY2025 annual result came in at $18175.0, up 333.98% from the prior year.
- Capital Expenditures improved to $4188.0 in Q4 2024, from $2157.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $11535.0 in Q2 2020 to a low of -$1.0 in Q4 2022.
- A 5-year average of $3620.4 and a median of $2533.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 100.05% — and 2023, when it surged 215800.0%.
- Tracing CNSP's Capital Expenditures over 5 years: stood at $11535.0 in 2020, then tumbled by 82.0% to $2076.0 in 2021, then slumped by 100.05% to -$1.0 in 2022, then surged by 215800.0% to $2157.0 in 2023, then surged by 94.16% to $4188.0 in 2024.
- The last three Capital Expenditures figures came in at $4188.0 (Q4 2024), $2157.0 (Q4 2023), and $1744.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 251.02 Mn |
| 10 | CNS Pharmaceuticals | 2.64 Mn | -4.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,188.00 |
| Dec 31, 2024 | 4,188.00 |
| Dec 31, 2023 | 2,157.00 |
| Dec 31, 2023 | 2,157.00 |
| Sep 30, 2023 | 1,744.00 |
| Sep 30, 2023 | 1,744.00 |
| Dec 31, 2022 | -1.00 |
| Dec 31, 2022 | -1.00 |
| Sep 30, 2022 | 1,514.00 |
| Sep 30, 2022 | 1,514.00 |
| Jun 30, 2022 | 2,909.00 |
| Jun 30, 2022 | 2,909.00 |
| Dec 31, 2021 | 2,076.00 |
| Dec 31, 2021 | 2,076.00 |
| Mar 31, 2021 | 3,672.00 |
| Mar 31, 2021 | 3,672.00 |
| Jun 30, 2020 | 11,535.00 |
| Jun 30, 2020 | 11,535.00 |
| Mar 31, 2020 | 6,410.00 |
| Mar 31, 2020 | 6,410.00 |